The AMR Narrative

Can diagnostic tests help to identify Antimicrobial Resistance (AMR)?

Can diagnostic tests help to identify Antimicrobial Resistance (AMR)?

Yes, of course they can! In this short blog we will learn what diagnostic tests are, and their valuable role in the management of infections, especially of those ones caused by Antimicrobial Resistant germs.

Let’s start from the basics. Diagnostic tests can detect the presence or absence of an infection, or alternatively point out evidence of a previous infection. They are very helpful tools not only to demonstrate the broad type of infection, (i.e., whether it is viral, bacterial, fungal, or caused by a parasite) but also to identify the type of microbial species responsible. Finally diagnostic tests can define an infection’s susceptibility (and resistance) to various antimicrobials medicines.

Diagnostic tests are based upon different investigations and technologies and, to simplify, we may divide them into two main groups:

  • The first group of diagnostic methods includes tests designed to detect the type of microorganism causing an infection. Microbiologists can use a microscope to directly visualise microorganisms (microscopy) or try to study the growth of the microorganism over time using what is called media on a petri dish (culture) which is then heated in an incubator. This helps them to detect nucleic acids (DNA or RNA) or proteins belonging to microbes (respectively molecular assays, and antigen detection assays).
  • The second group comprises tests able to measure human biomarkers. For example, some tests can identify biomarkers of infection, such as C reactive protein (CRP) produced by the human body in response to an infection, while other ones can detect antibodies, molecules made by the white blood cell to fight dangerous microbes.

So, what is the role of diagnostic tests in managing antimicrobial resistant infections?

Diagnostic tests can support clinicians to make an accurate diagnosis. Indeed, when managing patients with an infection, physicians need to identify the cause of the illness, to decide whether to prescribe an antimicrobial medicine like an antibiotic and, in this case, select the most appropriate one for a successful outcome.

On the contrary, prescribing an antimicrobial medicine without the help of diagnostics may increase the chance of an ineffective treatment. For example, an antibiotic which only treats bacterial infections can be prescribed unnecessarily for a viral infection.

On the other hand, an infection caused by a bacteria resistant to a certain class of antibiotics, might mistakenly be prescribed the wrong antibiotic instead of one that might be effective. Prescribing the wrong antimicrobial medicine for an infection that won’t respond to it can promote the emergence and further development of AMR

Therefore, the identification of microorganisms, and antimicrobial susceptibility or resistance may change the management of an infection, by enabling an early targeted therapy with proven activity against the microbe responsible for the disease. A correct diagnosis is paramount to using antimicrobial medicines appropriately.

Some traditional laboratory infection investigations have long turnaround times. For example, cultures require time for the microorganisms to grow, and therefore may take hours to days to provide a definitive result. However, today physicians can use rapid tests capable of returning reliable results within minutes to hours. They are especially useful during a patient visit to a health service, or in clinical situations requiring quick decisions, as in life-threatening infections. Point-of-care tests are performed near or at the site of a patient and can help clinicians in making a quick and correct diagnosis and defining an appropriate antimicrobial therapy.

Moreover, diagnostics play a crucial role in identifying asymptomatic individuals who are carriers of antibiotic-resistant bacteria in health care facilities. Screening tests enable infection prevention and control measures to be rapidly implemented, which is essential to prevent the spread of antimicrobial resistant infections among patients, and the development of outbreaks.

Finally, diagnostics support surveillance systems, because resistant microbes’ emergence and spread can be identified as early as possible and monitored in real time.

Although the emergence of resistant microorganisms is a natural phenomenon, both the overuse and inappropriate use of antimicrobials represent as the primary drivers of resistance.

Diagnostic tests can support physicians’ decisions, in this way contributing to reduce the unnecessary or ineffective use of antimicrobials, and preserving the effectiveness of these precious, but vulnerable, medicines for generations to come. As patients, it is equally beneficial to understand the role of diagnostics for AMR.

Francesco M. Labricciosa

Francesco M. Labricciosa is a Medical Doctor from Italy. After earning a post-graduate diploma in Primary Care Medicine, he consolidated his experience in different healthcare settings, and then became a specialist in Hygiene and Preventive Medicine.

Antimicrobial Resistance (AMR), optimal and prudent use of antimicrobials, and awareness towards consumption of these medications represent his main fields of interest.

Since 2016, he has been working with the Global Alliance for Infections in Surgery. He participated in several international research projects about prevention and management of healthcare-associated infections, surgical antibiotic prophylaxis, antimicrobial therapy in intra-abdominal infections, and antimicrobial stewardship programs. He has co-authored more than 40 articles published in peer-reviewed medical journals.

In 2023 he started an interesting collaboration with The AMR Narrative, serving as an Independent Advisor for the charity, and writing blogs to promote public understanding and education for AMR.

Moreover, Francesco works with several medical communication agencies in designing and finalising educational materials aimed at diversified audiences. Finally, he takes an active role in science communication blogging about antimicrobial use and AMR.

Chris Shaffer

Chris Shaffer was a music, special education teacher, and high school principal for 45 years. At the end of his educational career, he was thrust into the world of AMR infections when a number of abdominal surgeries left him with an E-coli infection which failed to respond to antibiotics. After doctors in the USA left him with little hope for a cure, diminishing health, and a bleak prognosis, he set out on his own.

Chris found success in phage therapy at the Eliava Phage Therapy Center in Tbilisi, Georgia. With phage therapy giving Chris his life back, he has dedicated his retirement years to advocating for and helping raise awareness of phage therapy used for AMR infections. He tells the story of his phage journey in a book titled, Finding Phage: How I Partnered with a Friendly Virus to Cure My Deadly Bacterial Superinfection. His website, phagetherpyusa.com helps others learn to understand the healing power of phage therapy.

Demi Christofi

Demi is an Associate Scientific Director at a medical communications agency, with a background in microbiology and a longstanding focus on antimicrobial resistance. She holds an MSc in Microbiology, where she first became interested in the global challenge of resistance and the need to bring scientific understanding to wider audiences.

Demi’s career has centred on a simple but powerful belief: that how we communicate science matters. Her work focuses on making complex data clear, engaging, and accessible – whether for healthcare professionals, policy makers, or the patients most affected by infection and resistance. She has contributed to a wide range of AMR-focused projects, including educational programmes, congress communications and stewardship initiatives.

A central thread in Demi’s work is the importance of the patient voice. She is passionate about making sure real-world experiences of treatment failure, recurrent infections, and the anxiety surrounding resistance are not lost in the data. She believes that listening to patients and involving them meaningfully is essential for shaping more effective, human-centred responses to AMR.

Demi is also a strong advocate of the One Health approach, recognising AMR as a complex, interconnected issue that spans human health, animal health, and the environment. She is particularly drawn to efforts that move beyond siloed thinking and focus on practical, joined-up solutions.

In 2025, Demi joined The AMR Narrative as an Independent Advisor, where she supports the charity’s mission to centre communication, community, and inclusion in the global AMR response.

Outside of work, she is a Girlguiding unit leader and a qualified yoga teacher. These roles reflect her commitment to care, learning, and creating supportive spaces for others.

Andrea Hartley

Andrea has worked in health communications and campaigning for 3 decades. She is committed to fighting AMR through timely and appropriate communications globally,.

Andrea set up Skating Panda, the creative social and environmental impact consultancy, over a decade ago and drives its impact and growth. Focused on original and lasting public interest communications as well as issue strategy and advocacy, the Panda team has a track record of prompting tipping points in the status quo that drive better social and planetary outcomes.

Andrea’s combination of commercial marketing and development experience with deep issue knowledge have been sought by decision-makers at global summits, corporate and NGO board members, and have enabled her to set up multi-million fundraising platforms and push through policies that change and save lives. 

Andrea is Vice Chair of mothers2mothers, the world’s largest employer of women living with HIV, and a Board Director of Maymessy, a food poverty social enterprise.

A lifelong advocate for gender equality, she played a key role in establishing the UK’s Women’s Equality Party.

Esmita Charani

Professor Esmita Charani is a pharmacist and researcher investigating how we use antibiotics in different cultural and social contexts. She works with teams in the UK, India, and South Africa to develop research programmes investigating all aspects of antimicrobial resistance in human populations with a focus in hospital settings.

She has experience in communicating her research with patients and the public through various media including animations, blogs, and educational videos.